Zacks Research Lowers Earnings Estimates for OPKO Health

OPKO Health, Inc. (NASDAQ:OPK) – Zacks Research dropped their Q3 2026 earnings estimates for shares of OPKO Health in a report released on Thursday, March 19th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.06). The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.29) EPS.

Several other analysts have also recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Barrington Research decreased their target price on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.03.

OPKO Health Price Performance

Shares of OPK opened at $1.12 on Monday. The business’s 50-day moving average is $1.23 and its 200-day moving average is $1.34. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.97 and a quick ratio of 3.52. The company has a market capitalization of $850.16 million, a price-to-earnings ratio of -3.73 and a beta of 1.50. OPKO Health has a fifty-two week low of $1.10 and a fifty-two week high of $1.83.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm had revenue of $148.50 million for the quarter, compared to analyst estimates of $139.76 million. During the same period in the previous year, the firm earned $0.01 earnings per share. OPKO Health’s quarterly revenue was down 19.1% on a year-over-year basis.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in OPKO Health by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock valued at $13,940,000 after acquiring an additional 67,973 shares during the last quarter. Millennium Management LLC grew its position in OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of OPKO Health by 150.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after purchasing an additional 3,600,378 shares during the last quarter. UBS Group AG raised its holdings in shares of OPKO Health by 12.1% during the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 577,248 shares in the last quarter. Finally, AWM Investment Company Inc. raised its holdings in shares of OPKO Health by 8.1% during the 2nd quarter. AWM Investment Company Inc. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,640,000 after purchasing an additional 150,000 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health News Summary

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Director John A. Paganelli purchased 10,000 shares at about $1.14, increasing his stake to 394,340 shares — insider buying often signals management confidence and can provide short‑term support. SEC Filing
• Positive Sentiment: Several institutional investors added or initiated positions in Q4 (e.g., World Investment Advisors, Virtu Financial, XTX Topco), indicating some institutional interest that can underpin the share base. MarketBeat Holdings Summary
• Neutral Sentiment: Analysts’ consensus remains a “Hold” rating on OPK (average price target near $2.03) — a mixed broker view that suggests limited near‑term conviction either way. Analyst Ratings Article
• Neutral Sentiment: Zacks published forward earnings commentary (including a FY2028 outlook) that highlights OPKO’s strengths (RAYALDEE sales, partnerships) but also calls out revenue decline and concentration risk — useful context for longer‑term investors. Zacks FY2028 Article
• Negative Sentiment: Zacks Research sharply cut near‑term and multi‑quarter EPS forecasts across Q3/Q4 2026–2027 and lowered FY2026/FY2027 estimates (many quarters now ~$(0.07)–$(0.08); FYs lowered toward ~$(0.29)). These downgrades meaningfully reduce profit expectations and are a primary driver of weaker investor sentiment today. Zacks Estimate Cuts (MarketBeat summary)
• Negative Sentiment: Barrington trimmed its price target from $2.25 to $1.50 (even while maintaining a constructive rating), which lowers the visible upside and can weigh on short‑term trading demand. Barrington PT Cut

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.